Amgen to Pay U.S. $24.9 Million to Resolve False Claims Act Allegations
Amgen Inc., a California-based biotechnology company, has agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act, the Justice Department announced today. Amgen develops, manufactures, and sells pharmaceutical products, including products sold under the trade name Aranesp.
Action Details
- Date:April 16, 2013
- Agency:U.S. Department of Justice
-
Enforcement Types:
- Criminal and Civil Actions